Post-marketing observational study (PMOS) Protocol
Showing 1 - 25 of >10,000
Study Assessing Safety and Efficacy of Nerivio for Migraine
Recruiting
- Migraine
- Nerivio
-
Bridgewater, New JerseyTheranica Inc USA
Jul 10, 2023
Brivaracetam:Prospective and Multicentre Post-marketing
Active, not recruiting
- Epilepsy
-
Montréal, Quebec, CanadaCentre Hospitalier de l'Université de Montréal (CHUM)
Jan 18, 2023
ALTUS Powered Stapler Used in Bariatric Surgery
Not yet recruiting
- Obesity
- Stapler
-
São Paulo, SP, BrazilHospital IGESP
Nov 29, 2022
BIOFLOW-china Post-marketing Study (BIOTRONIK)
Not yet recruiting
- In-Stent Stenosis (Restenosis) of Coronary Artery Stent
- Native Coronary Artery Stenosis
- BIOTRONIK Orsiro Sirolimus-Eluting Coronary Stent System
-
Harbin, Heilongjiang, ChinaThe Fourth Affiliated Hospital of Harbin Medical University
Dec 26, 2022
STEMI - ST Elevation Myocardial Infarction, Anterior MI Trial in Dresden (PiCSO)
Not yet recruiting
- STEMI - ST Elevation Myocardial Infarction
- Anterior MI
- PiCSO
-
Dresden, GermanyHerzzentrum Dresden GmbH Universitätsklinik an der TU Dresden
Aug 23, 2022
Moxetumomab Pasudotox-tdfk (LUMOXITI)
Recruiting
- Hairy Cell Leukemia
-
Pueblo, Colorado
- +1 more
Aug 17, 2022
Adult Diabetic Macular Edema and Suboptimal Response to
Not yet recruiting
- Diabetic Macular Edema
- (no location specified)
Jul 31, 2023
Multimodal Analgesic Protocol to Moderate Acute Pain
Recruiting
- Pain, Post-operative
- third molar surgery
-
Chapel Hill, North CarolinaUniversity of North Carolina School of Dentistry
Dec 2, 2022
Subcutaneous Infusion of ABBV-951 to Assess Change in Disease
Not yet recruiting
- Parkinson's Disease (PD)
- (no location specified)
Jun 15, 2023
Fibryga in Congenital Fibrinogen Deficiency
Recruiting
- Congenital Fibrinogen Deficiency
- Fibryga
-
Frankfurt, Germany
- +1 more
Jan 31, 2023
The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks Trial (Verzenios)
Not yet recruiting
- The Incidence of AEs and SAEs Receiving Verzenios® Over a Period of Approximately 24 Weeks
- Verzenios
- (no location specified)
Mar 3, 2022
(Special Use-results Surveillance on Long-term Use) With
Enrolling by invitation
- Adult Growth Hormone Deficiency
-
Fukuoka, Japan
- +6 more
Nov 8, 2022
Elonva (Corifollitropin Alfa) in General Practice (P08165)
Completed
- Infertility, Female
- corifollitropin alfa
- (no location specified)
Feb 1, 2022
Confirm the Safety and Efficacy of MARVELON (Study P06083)
Completed
- Contraception
- Ethinylestradiol + Desogestrel
- (no location specified)
Feb 2, 2022
Using Commercially Approved Biosense Webster Medical Devices for
Recruiting
- Cardiac Arrhythmias
- BWI Medical Device
-
Linz, Austria
- +13 more
Jan 23, 2023
(Use-results Surveillance) With Esperoct®
Enrolling by invitation
- Haemophilia A
- Turoctocog alfa pegol
-
Fukuoka, Japan
- +14 more
Nov 8, 2022
(PMS) Protocol of REKOVELLE Pre-Filled Pen (Follitropin Delta)
Recruiting
- Infertility, Female
- Other: Non intervention
-
Busan, Korea, Republic of
- +7 more
May 17, 2022
Nagor Perle Mammary Implants
Not yet recruiting
- Breast Reconstruction
- +7 more
- PERLE Sterile Smooth Opaque gel filled mammary implants
- (no location specified)
Aug 22, 2023
Vericiguat in Korean People With Chronic Heart Failure With
Not yet recruiting
- Chronic Heart Failure With Reduced Ejection Fraction
- Vericiguat (Verquvo, BAY1021189)
-
Multiple Locations, Korea, Republic ofMany Locations
Nov 20, 2023
EU Secondary Data Post-Authorisation Safety Study of AZD1222
Recruiting
- COVID-19, Vaccine Adverse Events of Special Interest
- AZD1222
-
Firenze, Italy
- +4 more
Jan 9, 2023
Oral Nutritional Supplement in Type 2 Diabetes or at Risk of
Not yet recruiting
- Malnutrition
- Diabetes
- Oral Nutritional Supplement (ONS)
- (no location specified)
Jun 21, 2023